Format

Send to

Choose Destination
J Clin Oncol. 2005 Nov 1;23(31):8136-9.

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.

PMID:
16258121
DOI:
10.1200/JCO.2005.02.5635
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center